Corruption Probe Could Be A Double-Edged Sword For Chinese Domestic Makers
This article was originally published in PharmAsia News
Chinese domestic pharmaceutical executives have been mostly tight-lipped about the government’s ongoing anti-corruption investigation, which has mainly targeted multinationals. But recent developments indicate that local companies may soon feel the heat.
You may also be interested in...
A regulatory pathway set up in China post-SARS is under stress test in the latest coronavirus outbreak, while emergency measures adopted by the country's regulator mean it’s much less burdensome to obtain approvals than before.
In a drastic move, China sends top physicians from around the country to Wuhan, finally allows a WHO expert delegation to visit hospitals in the outbreak's epicenter and welcomes foreign experts.